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Abstract
Extensive use of Viscum album (VA) preparations in the complementary therapy of cancer
and in several other human pathologies has led to an increasing number of cellular and mo-
lecular approaches to explore the mechanisms of action of VA. We have recently demon-
strated that, VA preparations exert a potent anti-inflammatory effect by selectively down-
regulating the COX-2-mediated cytokine-induced secretion of prostaglandin E2 (PGE2),
one of the important molecular signatures of inflammatory reactions. In this study, we ob-
served a significant down-regulation of COX-2 protein expression in VA-treated A549 cells
however COX-2 mRNA levels were unaltered. Therefore, we hypothesized that VA induces
destabilisation of COX-2 mRNA, thereby depleting the available functional COX-2 mRNA
for the protein synthesis and for the subsequent secretion of PGE2. To address this ques-
tion, we analyzed the molecular degradation of COX-2 protein and its corresponding mRNA
in A549 cell line. Using cyclohexamide pulse chase experiment, we demonstrate that, COX-
2 protein degradation is not affected by the treatment with VA whereas experiments on tran-
scriptional blockade with actinomycin D, revealed a marked reduction in the half life of
COX-2 mRNA due to its rapid degradation in the cells treated with VA compared to that in
IL-1β-stimulated cells. These results thus demonstrate that VA-mediated inhibition of PGE2
implicates destabilization of COX-2 mRNA.
Introduction
Cyclo-oxygenase-2 (COX-2) is an early response protein, up-regulated during many pathologi-
cal conditions and human malignancies. It is over expressed in most of the cells upon stimula-
tion with diverse pro-inflammatory stimuli such as pro-inflammatory cytokines, chemokines,
infectious agents, bacterial lipopolysaccharide etc. COX-2 is a critical enzyme required for the
biosynthesis of prostaglandin E2, one of the important molecular mediators of inflammation
[1]. Two other COX isoenzymes, COX-1 and COX-3, catalyze the same kind of reaction. COX-
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1 is an important cyclo-oxygenase family member, and is constitutively expressed in cells and
tissues, while precise functions are not known for COX-3, which is expressed only in some spe-
cific compartments including brain and spinal cord [2, 3]. The pattern of expression of COX-1
versus COX-2 further regulates their differential functions. COX-1 is constitutively and stably
expressed at low levels in many tissues. This ensures a constant production of prostaglandins,
which are essentially required for the maintenance of important physiological functions, such
as platelet aggregation, normal renal functions and gastric mucosal protection. In contrast,
COX-2 is mostly quiescent but the expression can be induced in response to diverse pro-in-
flammatory and pathogenic stimuli. When stimulated, its expression is high and transient
which leads to a burst of prostaglandin production in a regulated time-limited manner [4].
Thus, depending on the COX isoform, the production of the same precursor PGH2 from ara-
chidonic acid differs with respect to the amount and timing of production. This can be differ-
entially decoded by the cells, thereby leading to the activation of various intracellular pathways
involving specific classes of prostaglandins and therefore, different responses [5].
Since COX-2 expression is up-regulated during several pathological conditions and human
malignancies, strategies controlling the expression and activity of COX-2 have been developed
as potent anti-tumor and anti-inflammatory treatments [6–10]. In line with the therapeutic
benefit of non steroid anti-inflammatory drugs (NSAID), which are synthetically designed
mainly to inhibit the enzymatic activity of COX-2, a diverse spectrum of therapeutics of natural
origin such as phytotherapeutics have been characterized to evaluate their potential to inhibit
the COX-2 functioning thereby down-regulating the pathological level of prostaglandins. Due
to the structural homology between COX-1 and COX-2, most of the NSAID inhibit both the
enzymes and thus resulting in several severe side effects due to the inhibition of physiological
prostaglandins. Therefore, selective inhibitors of COX-2 are of great interest. Although, a
promising class of synthetic COX-2 selective inhibitors called COXIBS have been developed,
their therapeutic efficacy is compromised due to various side effects [11, 12]. Interestingly, sev-
eral phytotherapeutics have been shown to exert therapeutic benefit via selective inhibition of
COX-2. These natural molecules have been shown to interfere with the expression and regula-
tory mechanisms of COX-2 to inhibit its functioning [13, 14].
Viscum album (VA) preparations commonly called as mistletoe extracts, are extensively
used as complementary therapeutics in cancer and also in the treatment of several inflammato-
ry pathologies [15–19]. Despite their therapeutic application for several years, the underlying
mechanisms are not yet clearly understood. Several lines of evidence have revealed that these
preparations exert anti-tumor activities, which involve the cytotoxic properties, induction of
apoptosis, inhibition of angiogenesis and several other immunomodulatory and anti-inflam-
matory mechanisms [20–30]. These properties collectively define the mechanistic basis for the
therapeutic benefit of VA preparations. Recently we have shown that, VA preparations exert a
potent anti-inflammatory effect by selectively down-regulating the COX-2-mediated cytokine-
induced secretion of prostaglandin E2 (PGE2), one of the important molecular signatures of in-
flammatory reactions [31]. However, the molecular mechanisms associated with the Viscum-
mediated COX-2 inhibition are not clear. VA preparations are shown to inhibit the COX-2
protein expression without modulating its expression at mRNA level suggesting a possible ef-
fect of VA on post-transcriptional events of COX-2 regulation. Several molecules and phy-
totherapeutics are known to interfere with the post-transcriptional and post-translation
regulation of COX-2 in order to inhibit the COX-2 expression and subsequent reduction of
PGE2 [32–34]. Therefore in the current study, we investigated the post-transcriptional and
post-translational regulation of COX-2 by analyzing the stability of COX-2 protein and
mRNA, which can explain in part, the molecular mechanisms of Viscum-mediated COX-
2 inhibition.
Viscum album-Mediated COX-2 Inhibition
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Materials and Methods
Viscum album preparations
VA Qu Spez was a kind gift fromWeleda AG (Arlesheim, Switzerland). VA Qu Spez is a thera-
peutic preparation of Viscum album that grows on oak trees and is obtained as an isotonic solu-
tion of 10mg/ml formulated in 0.9% NaCl. It is free from endotoxins and contains the
standardized levels of mistletoe lectins.
Culture of A549 cells
Human lung adenocarcinoma cell line A549 was a kind gift from Dr. Maria Castedo-Delrieu,
Institute Gustave Roussy, Villejuif, France. A549 cells were grown in 75 cm2 culture flasks in
Dulbecco’s modified Eagle’s medium (DMEM) F-12 (GIBCO, Life Technologies, Grand Island,
NY, USA) supplemented with 10% fetal calf serum (FCS) and 50 U/ml penicillin and 50 μg/ml
of streptomycin (GIBCO). Cells are incubated at 37°C with 5% CO2 in humidified atmosphere
to obtain the cells of about 80–90% confluence and used for all experiments.
Co- and post- treatment of VA Qu Spez and induction of COX-2
Cells grown in complete medium (DMEM with 10% FCS) were harvested by trypsinisation
using 0.5% trypsin (Biological Industries, Kibbutz Beit Haemek, Israel) and were seeded in
12-well culture plates (0.5×106/ml cells per well). Wells containing the adherent A549 were
then replenished with the complete medium containing recombinant human IL-1β (10 ng/ml)
(Immuno Tools, Friesoythe, Germany). In one set of experiment VA Qu Spez is added at the
time of addition of IL-1 β (co-treatment) and in another set, we add VA Qu Spez 14 hours after
adding IL-1β (post-treatment) and both the sets were incubated until 18 hours at 37° C and 5%
CO2. After 18 hours of incubation cells were harvested by trypsinization and used for the anal-
ysis of COX-1/COX-2 protein by flow cytometry.
Analysis of the degradation profile of COX-2 protein by cyclohexamide
pulse chase experiment
A549 cells with an appropriate confluency were treated with IL-1β for 18 hours in the presence
or absence of VA Qu Spez. To block the protein synthesis 10 μg/ml of cyclohexamide (Sigma-
Aldrich, Lyon, France) was added after 90 minutes of addition of IL-1β and then cells were har-
vested at different time intervals as indicated to achieve a clear pattern of COX-2 degradation.
At each time point, expression of remaining COX-2 protein was analyzed by intracellular label-
ling, by flow cytometry and further validated by western blotting.
Analysis of COX-2 mRNA half-life by actinomycin D pulse chase
experiment
A549 cells with an appropriate confluency were treated with IL-1β for 4 hours in the presence
or absence of VA Qu Spez. After 4 hours, 10 μg/ml of actinomycin D (Sigma-Aldrich) was
added to the cells and cells were harvested by trypsinisation at different time intervals as indi-
cated. Expression of remaining COX-2 mRNA was analyzed by RT-PCR.
Statistical analysis
Densitometric analysis of the immunoblots was performed using BIO-1D analysis software.
Values are expressed as arbitrary units. All the observations are expressed as Mean ±SEM and
Viscum album-Mediated COX-2 Inhibition
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analyzed using two-way ANOVA. Graph-Pad Prism 5.0 is used for all the statistical analysis.
P values less than 0.05 were considered to be statistically significant.
Results
Co-treatment of A549 cell with IL-1β and Viscum album inhibits the
cytokine-induced COX-2 expression
Following our observation of the inhibition of cytokine-induced COX-2 expression, we investi-
gated the appropriate window of efficient inhibition by VA. Human lung adenocarcinoma
(A549) cells were stimulated with IL-1β for 18 hours in the presence or absence of VA Qu
Spez. VA was added to the cells either along with the cytokine (co-treatment) or after 14 hours
of IL-1β induction. Flow cytometric analysis of intracellular COX-2 expression demonstrated
that VA significantly inhibits cytokine-induced COX-2 expression as measured by mean fluo-
rescent intensity (MFI) only when it is added as a co-treatment with IL-1β but not when it was
added after 14 hours (Fig. 1A and 1B). This suggests that, VA-mediated COX-2 inhibition oc-
curs at the early phases of inflammatory process and opens other exploratory avenues to un-
derstand the regulatory mechanisms of COX-2 inhibition mediated by VA at the early phase
of inflammation.
Inhibition of COX-2 protein expression by Viscum album is independent
of modulation of stability of COX-2 protein
In order to address the effect of VA on the molecular stability of COX-2, which could be a po-
tential contributing factor for the observed reduction in COX-2 protein expression, we ana-
lyzed the stability of COX-2 protein. A549 cells were stimulated with a pro-inflammatory
cytokine IL-1β in the presence and absence of VA Qu Spez. At 18 hours, we observed a signifi-
cant reduction in COX-2 protein level treated with VA Qu Spez. Further, cells were harvested
at different time intervals after blocking the protein synthesis by treating the cells with cyclo-
hexamide and analyzed for COX-2. Flow cytometric analysis of COX-2 protein has revealed
that, there is no significant difference in the protein degradation profile of COX-2 in VA-treat-
ed and untreated cells after 90 minutes of blocking the protein synthesis (Fig. 2A and Fig. 2B).
Further, western blot analysis of COX-2 protein expression at different time intervals showed
that despite the clear inhibition in the protein expression after 18 hours of exposure to cytokine
followed by VA treatment (Fig. 3A), upon blocking the protein synthesis, there is no remark-
able difference in the COX-2 degradation profile in cells treated with cytokine irrespective of
VA treatment (Fig. 3B, 3C and 3D). Fig. 3B indicates the level of COX-2 expression immediate-
ly after 90 minutes of cyclohexamide addition (0 hour). Figs. 3C and 3D indicate the level of
COX-2 expression upon blocking the protein synthesis after 5 and 11 hours respectively. These
results may indicate that the regulation of COX-2 by VA may occur in an early phase of COX-
2 expression but not at the later stages of protein expression and stabilization.
Viscum album increases the COX-2mRNA degradation
Due to the indication of effect of VA in the early stages of COX-2 expression, but not at the
level of its mRNA expression, we analyzed the mRNA stability of COX-2 modulated by VA.
A549 cells were stimulated with IL-1β in the presence and absence of VA Qu Spez for 4 hours.
After 4 hours, cells were treated with actinomycin D and harvested at different time intervals.
Total cellular RNA was isolated and used for RT-PCR for the estimation of COX-2 mRNA.
Treatment with IL-1β is known to induce the expression of COX-2 mRNA by transcriptional
activation and also by increasing the stability of COX-2 mRNA. RT-PCR analysis of COX-2
Viscum album-Mediated COX-2 Inhibition
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mRNA expression at different time intervals after actinomycin D treatment revealed that, at
any given time interval there is a tendency to decline the relative expression of COX-2 mRNA
in VA-treated cells compared to the cells treated with IL-1β (Fig. 4A). This suggests that VA at
25 μg/ml increases the rate at which the COX-2 mRNA degrades in the absence of new mRNA
synthesis. Further, results from RT-PCR analysis have also showed COX-2 mRNA half life,
time required for 50% of the mRNA degradation in case of VA-treated cells was marginally re-
duced compared to that in case of cells stimulated with cytokine alone (Fig. 4B). This suggests
that VA is able to reduce the mRNA half-life of COX-2 thereby leading to its reduced bioavail-
ability for the protein synthesis.
Discussion
Prolonged administration of anti-inflammatory COX-2 inhibitors has been ineffective for che-
mopreventive and chemotherapeutic purposes since the risks prevail over the benefits. Clinical
demonstration of severe side effects due to the failure of the classical COX-2 inhibitors to dis-
criminate between an aberrant pathological versus homeostatic functional activation state,
raised the concern that direct COX-2 enzymatic inhibition might not sufficiently represent an
appropriate clinical strategy to target COX-2. Since in contrast to COX-1, COX-2 is an early re-
sponse gene, similar to the genes encoded for cytokines, chemokines and proto-oncogenes,
Fig 1. Co-treatment of A549 cell with IL-1β and Viscum album inhibits the cytokine-induced COX-2
expression. A549 cells were treated with IL-1β (10 ng/ml) and two different concentrations of Viscum album
QSpez preparation for 18 hours. Cytosolic COX-2 was measured using flow cytometric analysis. Viscum
album is added to the cells either from the beginning of the experiment along with IL-1β (co-treatment) or after
14 hours of IL-1β induction (post-treatment). Percentage COX-2 expression as measured in intracellular
staining by flow cytometry (A) and mean fluorescence intensity (MFI) of COX-2 expression (B) is shown.
Results are mean ±SEM of 4 independent experiments (**p<0.01; ***p<0.001).
doi:10.1371/journal.pone.0114965.g001
Viscum album-Mediated COX-2 Inhibition
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they can be regulated under different levels of expression and modulation, ranging from direct
transcriptional effects to post-transcriptional and post-translational levels and also indirectly
by various transcription factors that mediate the stability [32, 35]. Such multiple levels of mod-
ulation of COX-2 expression imply the existence of several mechanisms, which may be targeted
to finely modulate COX-2 functions [36–38]. Several phytotherapeutics have been shown to
exert modulatory effect on COX-2 at various levels of its molecular regulation and therefore
Fig 2. Effect of Viscum album on the stability of COX-2 protein as analyzed by flow cytometry. A549
cells were stimulated with IL-1β for 90 minutes with or without VA Qu Spez. Cells were harvested at different
time intervals after blocking the protein synthesis with cyclohexamide (10 μg/ml) for 90 minutes till 11 hours.
Normalised percentage COX-2 expression as measured in intracellular staining by flow cytometry (A) and
mean fluorescence intensity (MFI) of COX-2 expression (B) is shown. Data is representative of mean ±SEM
of three independent experiments.
doi:10.1371/journal.pone.0114965.g002
Viscum album-Mediated COX-2 Inhibition
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have been considered as an effective alternative strategy to control the pathogenic expression
of COX-2 [33, 39, 40]. Given that VA preparations exert a potent anti-inflammatory effect by
selective down regulation of COX-2, it is extremely interesting to dissect the COX-2 inhibition
mediated by VA in different regulatory mechanisms at molecular level.
Co-treatment of VA along with cytokine stimulation, marginally decreases COX-2 expres-
sion indicated by the percentage-positive COX-2 expression in Fig. 1A. However, VA signifi-
cantly inhibits intensity of expression of COX-2 as analyzed by MFI. The fact that VA
treatment at the later phases of cytokine induction does not inhibit COX-2 suggests that, inhi-
bition of COX-2 by VA occurs in the early phase of COX-2 regulation but not at the later
phases (Fig. 1). Since we observed an inhibition of COX-2 protein expression by VA but not of
mRNA, we analyzed the protein stability of COX-2 in the presence of VA by cyclohexamide
pulse chase experiments. Flow cytometric analysis of COX-2 expression after 90 minutes of
blocking the protein synthesis with cyclohexamide showed that, there is no significant differ-
ence in the COX-2 degradation profile of cells simulated with IL-1β with or without treatment
with VA (Fig. 2A and 2B). Western blot analysis of COX-2 protein after 5 and 11 hours of
cyclohexamide blockade showed no significant difference in the degradation pattern of COX-2
in cytokine stimulated cells with or without VA treatment (Fig. 3C and 3D). Similar results at
Fig 3. Effect of Viscum album on the stability of COX-2 protein as determined by western blot.Confluent A549 cells were treated with IL-1β in the
presence and absence of VA Qu Spez in dose dependent concentrations in μg/ml. Cells were harvested at different time intervals after blocking the protein
synthesis with cyclohexamide (10 μg/ml) for 90 minutes till 11 hours. COX-2 expression was measured by western blot using the cytosolic extracts. (A),
inhibition of COX2 protein synthesis by VA at 18 hours. (B) (C) (D) are the representative western blots after 90 minutes, 5 hours and 11 hours respectively
showing level of COX-2 expression after cyclohexamide treatment with or without Viscum album. β-actin was used as an internal control. All blots are
representative of three independent experiments and the densitometry values for each band are mentioned below the representative blots.
doi:10.1371/journal.pone.0114965.g003
Viscum album-Mediated COX-2 Inhibition
PLOS ONE | DOI:10.1371/journal.pone.0114965 February 9, 2015 7 / 11
different time points were observed (data not shown). Therefore, it is clear that COX-2 protein
degradation is not affected by VA. Further, reduced level of COX-2 expression at 0 hour in this
experiment (Fig. 3B) also suggests that, there may be modulation by VA of the COX-2 expres-
sion before the addition of inhibitor of protein synthesis. Inhibition of COX-2 protein expres-
sion by VA (Fig. 3A) without modulating its stability (Fig. 3B, 3C and 3D) strongly indicates
that, there is a possible modulation by VA at an early stage than when the proteins were ex-
pressed. However VA did not modulate COX-2 mRNA expression and therefore we analyzed
the mRNA stability of COX-2 by actinomycin D pulse chase experiment. mRNA degradation
Fig 4. Increase in the COX-2 mRNA degradation by Viscum album treatment. A549 cells were stimulated
with a pro-inflammatory cytokine IL-1β in the presence and absence of VA Qu Spez for 4 hours. After 4 hours
of IL-1β stimulation cells are blocked with actinomycin D (10 μg/ml). Cells were harvested at different time
intervals after adding actinomycin D and total cellular RNA was isolated and used for RT-PCR for the
estimation of COX-2 mRNA. Relative expression of remaining COX-2 mRNA at each time point, in VA treated
and untreated cells (A) and the time required for 50% of the mRNA degradation as COX-2 mRNA half life (B).
Data is obtained from three independent experiments.
doi:10.1371/journal.pone.0114965.g004
Viscum album-Mediated COX-2 Inhibition
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profile of COX-2 obtained by analyzing the COX-2 mRNA at different time intervals after
blocking the transcription using actinomycin D showed that the rate of degradation of COX-2
mRNA is higher in cells treated with VA compared to those treated with cytokine alone
(Fig. 4A). This reduction in the mRNA half-life of COX-2 in the cells treated with VA (Fig. 4B)
suggests that, VA induces destabilization of COX-2 mRNA, thereby diminishing the available
functional mRNA for the protein synthesis and for the subsequent secretion of PGE2.
Although this study postulates destabilization of COX-2 mRNA by VA preparations as a
possible mechanism for VA-mediated COX-2 inhibition, further molecular dissection is neces-
sary in order to clearly understand the regulatory events of COX-2 regulation, contributing fac-
tors and their modulation by VA preparations.
Conclusion
Increasing body of evidence for anti-inflammatory activity of plant-derived molecules by mod-
ulating the COX-2 functions has evolved as a potent alternative strategy for the conception of
novel therapeutic molecules in the treatment of various inflammatory pathologies and in vari-
ous malignancies. In view of the therapeutic benefit of VA preparations in diverse pathological
situations including inflammatory and cancer conditions, dissecting their molecular mecha-
nisms would contribute enormously to the understanding of role of phytotherapy-based treat-
ment strategies either in complementary or alternative medicine or in other
combinational therapies.
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